Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 3
2007 2
2008 2
2009 2
2010 2
2011 5
2012 9
2013 10
2014 12
2015 13
2016 15
2017 17
2018 17
2019 15
2020 11
2021 7
2022 7
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R, Mirtti T, Kilpeläinen TP, Tolonen T, Räisänen-Sokolowski A, Nordling S, Hannus J, Laurila M, Taari K, Tammela TLJ, Autio R, Natunen K, Auvinen A, Rannikko A. Hietikko R, et al. Among authors: taari k. World J Urol. 2024 Apr 6;42(1):217. doi: 10.1007/s00345-024-04898-2. World J Urol. 2024. PMID: 38581590 Free PMC article.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Natunen K, Nevalainen J, Raitanen J, Ronkainen J, van der Kwast T, Riikonen J, Pétas A, Matikainen M, Taari K, Kilpeläinen T, Rannikko AS; ProScreen Trial Investigators. Auvinen A, et al. Among authors: taari k. JAMA. 2024 Apr 6:e243841. doi: 10.1001/jama.2024.3841. Online ahead of print. JAMA. 2024. PMID: 38581254
Allopurinol and prostate cancer survival in a Finnish population-based cohort.
Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Kukko V, et al. Among authors: taari k. Prostate Cancer Prostatic Dis. 2024 Mar;27(1):73-80. doi: 10.1038/s41391-022-00597-4. Epub 2022 Sep 21. Prostate Cancer Prostatic Dis. 2024. PMID: 36131010 Free PMC article.
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
Salminen JK, Mehtola A, Talala K, Taari K, Mäkinen J, Peltola J, Tammela TLJ, Auvinen A, Murtola TJ. Salminen JK, et al. Among authors: taari k. Br J Cancer. 2022 Sep;127(4):704-711. doi: 10.1038/s41416-022-01817-3. Epub 2022 May 3. Br J Cancer. 2022. PMID: 35505251 Free PMC article. Clinical Trial.
Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A, Leht M, Mirtti T, Kenttämies A, Tolonen T, Rinta-Kiikka I, Kilpeläinen TP, Natunen K, Lilja H, Lehtimäki T, Raitanen J, Kujala P, Ronkainen J, Matikainen M, Petas A, Taari K, Tammela T, Auvinen A. Rannikko A, et al. Among authors: taari k. BJU Int. 2022 Aug;130(2):193-199. doi: 10.1111/bju.15683. Epub 2022 Jan 8. BJU Int. 2022. PMID: 34958531 Free PMC article. Clinical Trial.
128 results